GW Pharma expands into diabetes through university deal
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals is expanding its potential cannabinoid treatments to diabetes and metabolic disease after it signed a strategic alliance with Professor Mike Cawthorne at the University of Buckingham.